|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Tscan Therapeutics, Inc. (TCRX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
43,550,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TScan Therapeutics is a clinical-stage biopharmaceutical company focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. Co.'s proprietary platform is designed to: discover anti-cancer TCRs from patients with exceptional responses to immunotherapy; discover TCRs that recognize clinically validated targets; identify off-targets of TCRs to eliminate candidates; and manufacture TCR-T therapies using Co.'s T-Integrate technology. The central elements of Co.'s platform that differentiate it from other cell therapy companies are TargetScan, ReceptorScan, SafetyScan, ImmunoBank and T-Integrate.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,588,794 |
2,588,794 |
2,604,741 |
2,676,768 |
| Total Buy Value |
$3,106,553 |
$3,106,553 |
$3,193,217 |
$3,460,637 |
| Total People Bought |
1 |
1 |
2 |
3 |
| Total Buy Transactions |
2 |
2 |
6 |
10 |
| Total Shares Sold |
0 |
0 |
164,686 |
164,686 |
| Total Sell Value |
$0 |
$0 |
$952,116 |
$952,116 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2025-03-02 |
2024-11-29 |
2024-05-31 |
2023-06-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nichols Weston |
10% Owner |
– – • |
2025-05-20 |
4 |
B |
$1.20 |
$1,440,000 |
I/I |
1,200,000 |
7,946,141 |
1.5 |
- |
|
| Nichols Weston |
10% Owner |
– – • |
2025-05-19 |
4 |
B |
$1.20 |
$1,666,553 |
I/I |
1,388,794 |
6,746,141 |
1.5 |
- |
|
| Nichols Weston |
10% Owner |
– – • |
2024-11-15 |
4 |
B |
$4.34 |
$4,114 |
I/I |
947 |
5,225,547 |
1.42 |
- |
|
| Klencke Barbara |
|
– • – |
2024-09-23 |
4 |
B |
$5.29 |
$26,450 |
D/D |
5,000 |
45,000 |
0.01 |
- |
|
| Klencke Barbara |
|
– • – |
2024-08-26 |
4 |
B |
$5.53 |
$27,650 |
D/D |
5,000 |
40,000 |
0.01 |
- |
|
| Klencke Barbara |
|
– • – |
2024-08-23 |
4 |
B |
$5.69 |
$28,450 |
D/D |
5,000 |
35,000 |
0.01 |
- |
|
| Zdraveski Zoran |
See Remarks |
• – – |
2024-08-23 |
4 |
S |
$5.78 |
$952,116 |
D/D |
(164,686) |
4,716 |
|
- |
|
| Zdraveski Zoran |
See Remarks |
• – – |
2024-08-23 |
4 |
OE |
$1.81 |
$531,520 |
D/D |
157,186 |
169,402 |
|
- |
|
| Barberich Timothy J |
|
– • – |
2023-12-19 |
4 |
B |
$4.97 |
$1,575 |
D/D |
317 |
67,027 |
0.01 |
- |
|
| Barberich Timothy J |
|
– • – |
2023-12-18 |
4 |
B |
$4.89 |
$140,881 |
D/D |
28,830 |
66,710 |
0.01 |
- |
|
| Klencke Barbara |
|
– • – |
2023-12-14 |
4 |
B |
$5.08 |
$25,400 |
D/D |
5,000 |
30,000 |
0.01 |
- |
|
| Dworak Leiden |
Chief Accounting Officer |
• – – |
2023-07-21 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,692 |
|
- |
|
| Barberich Timothy J |
Director |
– • – |
2023-06-02 |
4 |
B |
$2.63 |
$99,564 |
D/D |
37,880 |
37,880 |
2.39 |
- |
|
| Nichols Weston |
10% Owner |
– – • |
2023-05-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,250,000 |
|
- |
|
| Nichols Weston |
10% Owner |
– – • |
2023-05-31 |
4 |
S |
$2.51 |
$38,805 |
I/I |
(15,400) |
5,224,600 |
|
- |
|
| Nichols Weston |
10% Owner |
– – • |
2023-05-31 |
4 |
S |
$2.51 |
$25,148 |
I/I |
(10,000) |
5,240,000 |
|
- |
|
| Ecor1 Capital, Llc |
10% Owner |
– – • |
2023-05-26 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,000,000 |
|
- |
|
| Klencke Barbara |
Director |
– • – |
2023-04-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
25,000 |
|
- |
|
| Klencke Barbara |
Director |
– • – |
2023-04-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,000 |
|
- |
|
| Silver Brian M. |
Chief Financial Officer |
• – – |
2022-12-28 |
4 |
B |
$1.56 |
$4,941 |
D/D |
3,158 |
32,885 |
2.66 |
- |
|
| Silver Brian M. |
Chief Financial Officer |
• – – |
2022-12-27 |
4 |
B |
$1.50 |
$4,276 |
D/D |
2,842 |
29,727 |
2.66 |
- |
|
| Southwell David P |
Chief Executive Officer |
• • – |
2022-05-18 |
4 |
B |
$3.55 |
$89,821 |
D/D |
25,000 |
171,569 |
2.81 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2022-05-11 |
4 |
B |
$1.99 |
$51,350 |
I/I |
25,865 |
2,528,583 |
2.25 |
- |
|
| Baker Brothers Life Sciences Lp |
Director |
– • • |
2022-05-10 |
4 |
B |
$1.70 |
$2,507,804 |
I/I |
1,333,927 |
2,505,600 |
2.25 |
- |
|
| Silver Brian M. |
Chief Financial Officer |
• – – |
2022-03-24 |
4 |
B |
$3.40 |
$50,982 |
D/D |
15,000 |
26,885 |
2.74 |
- |
|
38 Records found
|
|
Page 1 of 2 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
